US FDA approves Omeros drug Yartemlea for TA-TMA (first approved treatment for this dangerous post-transplant complication)

Intro

Welcome back to Breaking News to Trading Moves, where we turn market-moving headlines into long and short trading ideas. Today’s big biotech headline: the FDA approved Omeros’ Yartemlea for TA-TMA, a serious complication that can occur after stem cell transplants.

What happened

The FDA approved Omeros’ drug, branded Yartemlea (narsoplimab-wuug), for adults and children ages 2 and older with transplant-associated thrombotic microangiopathy, or TA-TMA.

Omeros shares jumped sharply on the news, reflecting how meaningful “FDA approval risk” being removed can be for small-cap biotech.

Why this matters

TA-TMA is dangerous because blood vessel damage and inflamma ...